| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 13 | 2021 | 1213 | 0.720 |
Why?
|
| Pancreatic Neoplasms | 5 | 2023 | 332 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 468 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 446 | 0.610 |
Why?
|
| Fanconi Anemia | 2 | 2016 | 7 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2020 | 331 | 0.580 |
Why?
|
| Benzimidazoles | 3 | 2016 | 128 | 0.560 |
Why?
|
| E2F3 Transcription Factor | 5 | 2019 | 46 | 0.540 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 6 | 0.540 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 9 | 0.540 |
Why?
|
| Mitomycin | 1 | 2016 | 27 | 0.530 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2021 | 87 | 0.530 |
Why?
|
| Neoplasms | 6 | 2019 | 1667 | 0.520 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 332 | 0.430 |
Why?
|
| Lung Neoplasms | 7 | 2019 | 1173 | 0.430 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2021 | 78 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1070 | 0.390 |
Why?
|
| E2F2 Transcription Factor | 4 | 2008 | 29 | 0.390 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2022 | 46 | 0.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2019 | 300 | 0.380 |
Why?
|
| E2F1 Transcription Factor | 4 | 2008 | 44 | 0.380 |
Why?
|
| Pyrimidinones | 3 | 2020 | 26 | 0.360 |
Why?
|
| Pyridones | 3 | 2020 | 40 | 0.360 |
Why?
|
| Mice | 22 | 2023 | 8474 | 0.360 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2017 | 231 | 0.350 |
Why?
|
| Glioma | 2 | 2021 | 140 | 0.340 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 75 | 0.340 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 206 | 0.330 |
Why?
|
| Transcriptome | 4 | 2019 | 164 | 0.320 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2019 | 34 | 0.310 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1293 | 0.310 |
Why?
|
| Cachexia | 2 | 2019 | 54 | 0.300 |
Why?
|
| DNA Modification Methylases | 3 | 2021 | 24 | 0.290 |
Why?
|
| DNA Repair Enzymes | 3 | 2021 | 53 | 0.290 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 371 | 0.290 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2017 | 22 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2015 | 68 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 629 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2021 | 194 | 0.270 |
Why?
|
| Cell Cycle | 4 | 2022 | 312 | 0.260 |
Why?
|
| Cell Proliferation | 7 | 2021 | 1174 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 208 | 0.250 |
Why?
|
| Animals | 22 | 2023 | 20881 | 0.240 |
Why?
|
| Cell Cycle Proteins | 3 | 2022 | 230 | 0.240 |
Why?
|
| Female | 27 | 2022 | 38074 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 627 | 0.230 |
Why?
|
| Humans | 36 | 2022 | 68618 | 0.230 |
Why?
|
| Paclitaxel | 3 | 2021 | 140 | 0.210 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2022 | 6 | 0.210 |
Why?
|
| Repressor Proteins | 2 | 2019 | 183 | 0.200 |
Why?
|
| Neural Stem Cells | 1 | 2022 | 32 | 0.200 |
Why?
|
| Gliosarcoma | 1 | 2021 | 4 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2021 | 6 | 0.200 |
Why?
|
| Exome | 1 | 2021 | 20 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 213 | 0.200 |
Why?
|
| Gene Amplification | 2 | 2019 | 71 | 0.200 |
Why?
|
| Pancreas | 1 | 2023 | 225 | 0.200 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2021 | 3 | 0.200 |
Why?
|
| Male | 22 | 2022 | 37321 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 1 | 2021 | 39 | 0.190 |
Why?
|
| Fibroblasts | 7 | 2023 | 902 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 41 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 756 | 0.190 |
Why?
|
| E2F4 Transcription Factor | 2 | 2019 | 9 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 4 | 2021 | 104 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 18 | 0.180 |
Why?
|
| Transcription Factors | 3 | 2015 | 753 | 0.180 |
Why?
|
| Adherens Junctions | 1 | 2020 | 13 | 0.180 |
Why?
|
| Prognosis | 6 | 2021 | 2093 | 0.180 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 1851 | 0.180 |
Why?
|
| Carboplatin | 2 | 2019 | 59 | 0.180 |
Why?
|
| Nuclear Proteins | 3 | 2015 | 271 | 0.170 |
Why?
|
| DNA Repair | 2 | 2019 | 127 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 19 | 0.170 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 43 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 20 | 0.170 |
Why?
|
| Homologous Recombination | 1 | 2019 | 13 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 24 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2021 | 108 | 0.170 |
Why?
|
| Liposarcoma | 1 | 2019 | 13 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 25 | 0.170 |
Why?
|
| Colon | 1 | 2020 | 168 | 0.170 |
Why?
|
| RNA Interference | 1 | 2020 | 266 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.160 |
Why?
|
| Middle Aged | 12 | 2021 | 21147 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 304 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2019 | 284 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 124 | 0.150 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 27 | 0.150 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2017 | 14 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 567 | 0.150 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2017 | 4 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 17 | 0.150 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 6 | 0.150 |
Why?
|
| Arthralgia | 1 | 2017 | 30 | 0.150 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 508 | 0.150 |
Why?
|
| Melanoma | 1 | 2021 | 335 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2020 | 431 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 800 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 69 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 306 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 99 | 0.140 |
Why?
|
| Models, Biological | 2 | 2020 | 981 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 5 | 2021 | 615 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2016 | 2689 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 116 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 82 | 0.140 |
Why?
|
| Carcinogenesis | 3 | 2023 | 124 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 1 | 2016 | 15 | 0.130 |
Why?
|
| Machine Learning | 1 | 2017 | 170 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2016 | 17 | 0.130 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 35 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2015 | 9 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 47 | 0.130 |
Why?
|
| Pedigree | 1 | 2016 | 159 | 0.130 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2015 | 31 | 0.130 |
Why?
|
| Diarrhea | 1 | 2016 | 63 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 223 | 0.130 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2015 | 2 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 82 | 0.130 |
Why?
|
| Genetic Vectors | 1 | 2016 | 312 | 0.130 |
Why?
|
| Citrus | 1 | 2015 | 12 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 122 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 64 | 0.130 |
Why?
|
| Carotenoids | 1 | 2015 | 45 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2015 | 25 | 0.120 |
Why?
|
| Fatigue | 1 | 2016 | 132 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1034 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2015 | 64 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2015 | 112 | 0.120 |
Why?
|
| Aged | 7 | 2021 | 14862 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2550 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 331 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 150 | 0.120 |
Why?
|
| Heterografts | 3 | 2020 | 70 | 0.120 |
Why?
|
| Mice, Knockout | 5 | 2019 | 1692 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2021 | 714 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 167 | 0.120 |
Why?
|
| Carcinoma | 1 | 2015 | 215 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 475 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7029 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2023 | 235 | 0.110 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 700 | 0.110 |
Why?
|
| Genotype | 4 | 2015 | 786 | 0.100 |
Why?
|
| DNA Methylation | 3 | 2021 | 193 | 0.100 |
Why?
|
| Adult | 7 | 2020 | 21403 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 561 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.090 |
Why?
|
| Cells, Cultured | 6 | 2019 | 2673 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1536 | 0.090 |
Why?
|
| E2F Transcription Factors | 2 | 2008 | 48 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2022 | 305 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 320 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 111 | 0.090 |
Why?
|
| RNA-Binding Proteins | 2 | 2021 | 215 | 0.080 |
Why?
|
| Genomics | 2 | 2021 | 168 | 0.080 |
Why?
|
| Growth | 1 | 2008 | 17 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 536 | 0.080 |
Why?
|
| Morpholines | 2 | 2019 | 79 | 0.080 |
Why?
|
| Embryo, Mammalian | 4 | 2015 | 176 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1553 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1174 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2008 | 100 | 0.070 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 357 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 951 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 170 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 58 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 75 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 498 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 97 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 349 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 2791 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 396 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 562 | 0.060 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 43 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2019 | 7277 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 1200 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2004 | 137 | 0.060 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2003 | 14 | 0.060 |
Why?
|
| Centrosome | 1 | 2003 | 6 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 786 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.050 |
Why?
|
| X Chromosome Inactivation | 1 | 2022 | 2 | 0.050 |
Why?
|
| Ependymoglial Cells | 1 | 2022 | 7 | 0.050 |
Why?
|
| DNA Replication | 1 | 2003 | 167 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 47 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 852 | 0.050 |
Why?
|
| Mesoderm | 1 | 2023 | 231 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 51 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2022 | 146 | 0.050 |
Why?
|
| Neuroglia | 1 | 2022 | 136 | 0.050 |
Why?
|
| Homeostasis | 1 | 2023 | 291 | 0.050 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.050 |
Why?
|
| Procarbazine | 1 | 2020 | 1 | 0.050 |
Why?
|
| Lomustine | 1 | 2020 | 10 | 0.050 |
Why?
|
| Vincristine | 1 | 2020 | 44 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2021 | 116 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2020 | 16 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 132 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 266 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 84 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 199 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 54 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 155 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 56 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 130 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2019 | 31 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 160 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 72 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 219 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 137 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2019 | 83 | 0.040 |
Why?
|
| Pyrroles | 1 | 2019 | 83 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 126 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 630 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 689 | 0.040 |
Why?
|
| Cell Survival | 1 | 2021 | 901 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 248 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 792 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 386 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2019 | 178 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 659 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2017 | 5 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 25 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 39 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 42 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 41 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 5717 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2017 | 40 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 299 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 72 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 373 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2016 | 26 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 48 | 0.030 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 138 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4848 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 47 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 563 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 254 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 58 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 238 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 1752 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2015 | 12 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 81 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 25 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 35 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 33 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 159 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 597 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2015 | 11 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 247 | 0.030 |
Why?
|
| zeta Carotene | 1 | 2015 | 1 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 90 | 0.030 |
Why?
|
| Transposases | 1 | 2015 | 1 | 0.030 |
Why?
|
| Isomerism | 1 | 2015 | 63 | 0.030 |
Why?
|
| Hematocrit | 1 | 2015 | 70 | 0.030 |
Why?
|
| Genomic Library | 1 | 2015 | 18 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 1 | 2015 | 49 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2008 | 235 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 447 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 79 | 0.030 |
Why?
|
| Sonication | 1 | 2015 | 8 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 220 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 62 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 129 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 139 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 219 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 184 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 554 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 120 | 0.030 |
Why?
|
| E2F7 Transcription Factor | 2 | 2005 | 15 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 260 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 381 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2015 | 161 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 239 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 791 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 331 | 0.030 |
Why?
|
| Phenotype | 2 | 2008 | 947 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3259 | 0.030 |
Why?
|
| Apoptosis | 1 | 2019 | 1641 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3705 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 867 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2324 | 0.020 |
Why?
|
| Embryo Loss | 1 | 2008 | 17 | 0.020 |
Why?
|
| G1 Phase | 1 | 2006 | 42 | 0.020 |
Why?
|
| S Phase | 1 | 2006 | 38 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 5731 | 0.020 |
Why?
|
| E2F6 Transcription Factor | 1 | 2005 | 2 | 0.020 |
Why?
|
| E2F5 Transcription Factor | 1 | 2005 | 4 | 0.020 |
Why?
|
| Gene Library | 1 | 2005 | 68 | 0.020 |
Why?
|
| Dimerization | 1 | 2005 | 99 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Growth Differentiation Factor 10 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2003 | 3 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1033 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 29 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 2003 | 18 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 84 | 0.010 |
Why?
|
| Cyclin E | 1 | 2003 | 19 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 21 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 251 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 130 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1083 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 60 | 0.010 |
Why?
|
| United States | 1 | 2015 | 7367 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 246 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 322 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1447 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 541 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 8912 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 489 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 631 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 782 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 954 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 597 | 0.010 |
Why?
|